Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
12.06. | VISEN PHARMA-B (02561): SUPPLEMENTAL NOTICE OF ANNUAL GENERAL MEETING | 2 | HKEx | ||
12.06. | VISEN PHARMA-B (02561): SECOND FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, 27 JUNE 2025 AT 3:00 P.M. | 1 | HKEx | ||
12.06. | VISEN PHARMA-B (02561): (1) CONTINUING CONNECTED TRANSACTION IN RELATION TO THE COMMERCIAL SUPPLY FRAMEWORK AGREEMENT; (2) PROPOSED GRANT OF AWARD SHARES; ... | - | HKEx | ||
VISEN PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
12.06. | VISEN PHARMA-B (02561): GRANT OF AWARD SHARES | 3 | HKEx | ||
12.06. | VISEN PHARMA-B (02561): CONTINUING CONNECTED TRANSACTION COMMERCIAL SUPPLY FRAMEWORK AGREEMENT | - | HKEx | ||
30.04. | VISEN PHARMA-B (02561): NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
30.04. | VISEN PHARMA-B (02561): FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, 27 JUNE 2025 AT 3:00 P.M. | - | HKEx | ||
30.04. | VISEN PHARMA-B (02561): (1) PROPOSED RE-ELECTION OF RETIRING DIRECTORS; (2) PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE SHARES ... | - | HKEx | ||
30.04. | VISEN PHARMA-B (02561): 2024 ANNUAL REPORT | - | HKEx | ||
25.04. | VISEN PHARMA-B (02561): NOTIFICATION LETTER TO NON-REGISTERED SHAREHOLDERS AND REPLY FORM | 1 | HKEx | ||
25.04. | VISEN PHARMA-B (02561): NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS AND REPLY FORM | 1 | HKEx | ||
17.04. | VISEN PHARMA-B (02561): STABILIZING ACTIONS, END OF STABILIZATION PERIOD AND LAPSE OF THE OVER-ALLOTMENT OPTION | 3 | HKEx | ||
27.03. | VISEN PHARMA-B (02561): FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2024 | - | HKEx | ||
24.03. | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA 24.03.2025 | 494 | Xetra Newsboard | The following instruments on XETRA do have their first trading 24.03.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 24.03.2025
Aktien
1 KYG93Y5D1039 VISEN Pharmaceuticals
2... ► Artikel lesen | |
20.03. | VISEN PHARMA-B (02561): ANNOUNCEMENT OF ALLOTMENT RESULTS | 2 | HKEx | ||
20.03. | VISEN PHARMA-B (02561): CLARIFICATION ANNOUNCEMENT IN RELATION TO PRINCIPAL PLACE OF BUSINESS IN HONG KONG | 1 | HKEx | ||
19.03. | VISEN PHARMA-B (02561): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 2 | HKEx | ||
19.03. | VISEN PHARMA-B (02561): TERMS OF REFERENCE OF THE NOMINATION COMMITTEE | 5 | HKEx | ||
19.03. | VISEN PHARMA-B (02561): TERMS OF REFERENCE OF THE REMUNERATION COMMITTEE | 1 | HKEx | ||
19.03. | VISEN PHARMA-B (02561): TERMS OF REFERENCE OF THE AUDIT COMMITTEE | 3 | HKEx |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 40,960 | -0,65 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
TARSUS PHARMACEUTICALS | 40,330 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements | Generated $78.3 million in net product sales of XDEMVY®, an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles to patients Strengthened financial position... ► Artikel lesen | |
EVOTEC | 7,144 | -0,72 % | Evotec-Aktie: Kurs legt zu (6,734 €) | Am deutschen Aktienmarkt notiert die Evotec-Aktie derzeit etwas fester. Zuletzt zahlten Investoren für das Wertpapier 6,73 Euro. Der Anteilsschein von Evotec verzeichnet gegenwärtig einen Preisanstieg... ► Artikel lesen | |
BIONTECH | 90,90 | +0,28 % | Die nächste Cashcow? Schnelle Prozente mit NetraMark, Moderna, BioNTech | Erinnern Sie sich noch an den Impfstoff-Wettlauf in der Corona-Zeit? Damals bestimmte das Duell zwischen BioNTech und Curevac auch das Geschehen an der Börse. Anleger der ersten Stunde machten schnell... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,355 | -1,02 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
ADMA BIOLOGICS | 18,150 | -1,25 % | Will Strong Asceniv Sales Drive ADMA Biologics Further? | ||
PHATHOM PHARMACEUTICALS | 9,550 | 0,00 % | Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
EDGEWISE THERAPEUTICS | 13,050 | 0,00 % | Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies | - New open label data in Becker demonstrated sustained disease stabilization up to three years, reinforcing prior clinical findings -- Ongoing pivotal trial and FDA Type C meeting provide... ► Artikel lesen | |
ONCO-INNOVATIONS | 1,340 | +7,20 % | EQS-Media: Onco-Innovations Ltd.: Erhebliche Aufwärtsperspektive für frühe Investoren? Neue Studie unterstützt die Anwendbarkeit der Ergebnisse klinischer Lungenkrebsstudien | EQS-Media / 21.06.2025 / 15:37 CET/CEST
Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, freut sich bekannt zu geben, dass die Mitbegründer seiner hundertprozentigen... ► Artikel lesen | |
ARS PHARMACEUTICALS | 18,090 | 0,00 % | ARS Pharmaceuticals, Inc. - 8-K, Current Report | ||
ARCELLX | 64,79 | 0,00 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
SEPTERNA | 10,870 | 0,00 % | Analyst Flags Septerna As Undervalued Biotech Play With Significant Upside | ||
NUVALENT | 79,24 | 0,00 % | Nuvalent, Inc.: Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | Aligned with FDA on NDA submission strategy for TKI pre-treated patients with advanced ROS1-positive NSCLC and participation in Real-Time Oncology Review; the... ► Artikel lesen | |
LEXEO THERAPEUTICS | 4,180 | 0,00 % | Lexeo to help launch spinout around RNA drugs for the heart | ||
KINIKSA PHARMACEUTICALS | 28,480 | 0,00 % | Kiniksa Pharmaceuticals, Ltd.: Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis | - KPL-387 Phase 2/3 trial on track to initiate in mid-2025; Phase 2 data expected in 2H 2026 -- KPL-387 Phase 1 single ascending dose data support profile for monthly dosing -- Presentation and webcast... ► Artikel lesen |